Mesothelioma 
Welcome,         Profile    Billing    Logout  

278 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mesothelioma
NCT06057935: A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Recruiting
2
64
US
Pemetrexed, Cisplatin, Carboplatin
Memorial Sloan Kettering Cancer Center
Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
09/28
09/28
NCT03935893: Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Recruiting
2
240
US
Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination, Fludara; Cytoxan
Udai Kammula
Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma, Mesothelioma, Neuroendocrine Tumors, Squamous Cell Cancer, Merkel Cell Carcinoma, Mismatch Repair Deficiency, Microsatellite Instability
06/36
06/37
NCT05500508: Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Recruiting
1b/2a
56
US, RoW
AMXT1501, DFMO, difluoromethyl ornithine monohydrochloride
Aminex Therapeutics, Inc.
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
06/24
09/24
MANTRA-4, NCT06090318: Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Withdrawn
1b/2
NA
Milademetan, RAIN-32, Atezolizumab, TECENTRIQ
Rain Oncology Inc
Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
05/23
05/23
ACTRN12620001264976: Novel Delivery of Chemotherapy for Treatment of Patients with Mesothelioma: A Feasibility Study

Recruiting
1/2
6
 
I-MED Radiology, I-MED Radiology Network
Malignant pleural mesothelioma
 
 
2015-003928-31: FAK-PD1 - A Phase I/IIa Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies.

Not yet recruiting
1/2
59
Europe
Defactinib (VS-6063), Pembrolizumab (MK-3475), VS-6063, MK-3475, Tablet, Powder for concentrate for solution for infusion, KEYTRUDA
NHS Greater Glasgow and Clyde, University Of Glasgow, , CRUK New Agents Committee, MSD, Verastem Inc
Advanced, incurable cancer with no remaining standard-of-care treatment options that are suitable. Or where pembrolizumab is a licensed treatment option at that line of therapy. In Phase I, this may be any solid cancer. In Phase II, this will be pancreatic cancer, non-small cell lung cancer (NSCLC) or mesothelioma., Incurable cancer with no remaining standard treatment options that they should have first. All cancer types in the first part, then just pancreatic, non-small cell lung and mesothelioma in the second., Diseases [C] - Cancer [C04]
 
 
SWOG S0905, NCT01064648: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Active, not recruiting
1/2
117
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration
National Cancer Institute (NCI)
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
06/18
03/25
NCT03233724: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Terminated
1/2
9
US
Decitabine (DAC), Dacogen, Tetrahydrouridine (THU), Pembrolizumab, Keytruda
National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
10/21
10/21
KEYNOTE-C49, NCT03834948: AO-176 in Multiple Solid Tumor Malignancies

Completed
1/2
57
US
AO-176, AO-176 + Paclitaxel, AO-176 + Pembrolizumab
Arch Oncology, Merck Sharp & Dohme LLC
Solid Tumor
11/22
02/23
2021-003229-31: Integration of immunotherapy into first-line chemotherapy voor patients with epithelioid malignant pleural mesothelioma Toevoeging van immuuntherapie aan de eerstelijnschemotherapie voor patiënten met epitheliale longvlieskanker

Not yet recruiting
1/2
15
Europe
cryopreserved Wilms' tumor 1 (WT1) mRNA-electroporated dendritic cells, WT1/DC, Suspension for injection, Concentrate for solution for infusion, Tecentriq
Antwerp University Hospital, Kom op tegen Kanker, NV Roche SA
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV) Maligne pleuraal mesothelioma, epithelioïde subtype (stadium I-IV), Asbestos cancer Asbestkanker (longvlieskanker), Diseases [C] - Cancer [C04]
 
 
NCT02535312: Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Active, not recruiting
1/2
30
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Methoxyamine, TRC102 Base, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
12/22
10/24
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Recruiting
1/2
73
RoW
CAR-T cell immunotherapy
Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University
B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma
03/23
03/23
NCT03319537: Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Terminated
1/2
9
US
pevonedistat, Pemetrexed and cisplatin
Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center
Mesothelioma
06/23
06/23
RAPTOR, NCT04301011: Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

Terminated
1/2
27
Canada, US, RoW
TBio-6517, RIVAL-01, Pembrolizumab, Keytruda
Turnstone Biologics, Corp., Takeda
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
01/23
01/23
NCT03126630: Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Active, not recruiting
1/2
46
Canada, US
Anetumab Ravtansine, BAY 94-9343, Laboratory Biomarker Analysis, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Pharmacological Study
National Cancer Institute (NCI)
Pleural Malignant Mesothelioma
07/23
09/24
NCT00797719: Short Neoadjuvant Hemithoracic IMRT for MPM

Active, not recruiting
1/2
100
Canada
Pre-op RT +/- chemotherapy
University Health Network, Toronto
Malignant Pleural Mesothelioma
09/24
09/24
PM1183-A-014-15, NCT02611024: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Recruiting
1/2
320
Europe, US
Lurbinectedin, PM01183, Irinotecan
PharmaMar
Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
03/26
03/26
MESODEC, NCT02649829: Autologous Dendritic Cell Vaccination in Mesothelioma

Active, not recruiting
1/2
28
Europe
dendritic cell vaccination plus chemotherapy, chemoimmunotherapy
University Hospital, Antwerp, Kom Op Tegen Kanker, Stichting tegen Kanker
Malignant Pleural Mesothelioma
03/25
03/25
NCT04665206: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations

Recruiting
1/2
250
US, RoW
VT3989
Vivace Therapeutics, Inc
Solid Tumor, Adult, Mesothelioma
12/26
06/27
NCT02414269: Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Active, not recruiting
1/2
113
US
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Memorial Sloan Kettering Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
04/25
04/25
NCT06362369: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Recruiting
1/2
126
US
Alintegimod, 7HP349, Ipilimumab, Yervoy, Nivolumab, Opdivo
7 Hills Pharma, LLC
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
12/27
12/28
NCT05598268: A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

Recruiting
1/2
74
RoW
T3011
ImmVira Pharma Co. Ltd
Advanced Solid Tumor, Lung Cancer, Liver Cancer, Lymphoma, Mesothelioma of Pleura
06/24
12/24
NCT03907852: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting
1/2
36
Canada, US
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
TCR2 Therapeutics, Bristol-Myers Squibb
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
11/28
11/28
NCT05714553: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Recruiting
1/2
91
Europe
Fosifloxuridine Nafalbenamide, NUC-3373, Nucleotide analogue, Leucovorin, Folinic acid, Levo-leucovorin, Pembrolizumab, Keytruda, Docetaxel, Taxotere, Docecad, Docefrez
NuCana plc
Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Subungual Squamous Cell Carcinoma, Oesophageal Carcinoma, MSI-H Colorectal Cancer, Gastric Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Pleural Mesothelioma
08/24
01/25
ABILITY-1, NCT05086692: A Beta-only IL-2 ImmunoTherapY Study

Recruiting
1/2
115
Canada, US, RoW
MDNA11, Interleukin-2 (IL-2)-albumin, Pembrolizumab
Medicenna Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer
06/26
12/26
ICEMELT, NCT04631731: Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

Recruiting
1/2
200
RoW
Blood screening, Tissue screening
Western Sydney Local Health District, University of Western Sydney, Bristol-Myers Squibb
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer, Hepatocellular Carcinoma, Endometrial Cancer, Mesothelioma
12/24
12/25
TRuST, NCT02875548 / 2015-004984-35: A Study to Assess the Long-term Safety of Tazemetostat

Enrolling by invitation
1/2
100
Europe, US, RoW
Tazemetostat, EPZ-6438, E7438, IPN60200
Epizyme, Inc.
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
11/25
11/25
REGOMUNE, NCT03475953: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Recruiting
1/2
747
Europe
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib
Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural
12/24
12/25
PRO1184-001, NCT05579366: PRO1184 for Advanced Solid Tumors

Recruiting
1/2
374
US, RoW
PRO1184, PRO1184 intravenous infusion of PRO1184
ProfoundBio US Co.
Ovarian Cancer, High Grade Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer
10/25
04/26
KEYNOTE-D25, NCT04913337: Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Active, not recruiting
1/2
179
US, RoW
NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
NGM Biopharmaceuticals, Inc, Merck Sharp & Dohme LLC
Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
02/25
07/25
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
NCT05275478: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
NCT05451849: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting
1/2
6
US
TC-510, Fludarabine, Cyclophosphamide
TCR2 Therapeutics
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
10/28
10/28
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
842
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
NCT05703854: Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Recruiting
1/2
50
US
CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Neosar®
M.D. Anderson Cancer Center
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
09/25
09/27
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
INTERACT MESO, NCT05449366: Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

Recruiting
1/2
21
Europe
Intraperitoneal Paclitaxel Solution (Ml), Paclitaxel
Erasmus Medical Center
Peritoneal Malignant Mesothelioma
02/26
02/26
NCT05245500: Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Recruiting
1/2
370
US
MRTX1719
Mirati Therapeutics Inc.
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
04/26
04/26
NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
159
Europe, US
TNG462
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
NCT05944237: HTL0039732 in Participants With Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Heptares Therapeutics Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
09/26
09/26
Immuno-MESODEC, NCT05765084: Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Recruiting
1/2
15
Europe
Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
University Hospital, Antwerp, Algemeen Ziekenhuis Maria Middelares, Vitaz, Kom Op Tegen Kanker, Roche Pharma AG
Malignant Pleural Mesothelioma
10/26
10/26
NCT05932199: Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Not yet recruiting
1/2
52
US
Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Baylor College of Medicine, Duke Cancer Institute
Mesothelioma
05/28
05/28
EVEREST-2, NCT06051695: A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Recruiting
1/2
230
US
A2B694, Tmod CAR T-cell Therapy, xT CDx with HLA-LOH Assay
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
06/28
06/29
NCT05795595: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Recruiting
1/2
250
US
CTX131
CRISPR Therapeutics AG
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
04/30
05/30
NCT05627960: First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Recruiting
1a
77
US
AG-01 Compound
A&G Pharmaceutical Inc., University of Maryland Greenebaum Cancer Center
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
06/26
11/26
ACTRN12624000268549: LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma

Not yet recruiting
1
18
 
ADDRI, Insurance and Care NSW
Mesothelioma
 
 
ACTRN12609000260224: Optimising regulatory T cell depletion with cyclophosphamide in combination with chemotherapy for enhanced anti-tumour immunity in patients with non-small cell lung cancer (NSCLC) and malignant mesothelioma (MM).

Recruiting
1
33
 
Sir Charles Gairdner Hospital, National Health and Medical Research Council (NHMRC)
Malignant Mesothelioma, Non small cell lung cancer
 
 
ACTRN12614001248651: The first testing of TargomiRs in the human setting: dose-finding studies in patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer

Recruiting
1
30
 
Asbestos Disease Research Institute, Asbestos Disease Research Foundation, EnGeneIC
Malignant Pleural Mesothelioma , Advanced Non Small Cell Lung Cancer
 
 
ACTRN12609000294257: CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study

Completed
1
15
 
Sir Charles Gairdner Hospital, Pfizer Australia (research grant-in-aid for investigator initiated study)
unresectable malignant pleural mesothelioma
 
 
ChiCTR-OIC-16007996: Open-label, uncontrolled, single-arm pilot study to evaluate cellular immunotherapy using mesothelin-targeted chimeric antigen receptor engineered T cells in patients with mesothelin+ malignant pleural mesothelioma and pancreatic carcinoma.

Not yet recruiting
1
30
 
anti-meso CART cells
Renji Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai GeneChem Co., Ltd., Shanghai GeneChem Co.,Ltd.
malignant pleural mesothelioma and pancreatic carcinoma
 
 
NCT04034238: Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Completed
1
19
US
LMB-100, Tofacitinib, Xeljanz, Mesothelin Expression
National Cancer Institute (NCI)
Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
12/20
11/21
CK-301-101, NCT03212404: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Recruiting
1
500
Europe, RoW
CK-301 (cosibelimab)
Checkpoint Therapeutics, Inc., Novotech (Australia) Pty Limited
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Classical Hodgkin Lymphoma, Cutaneous Squamous Cell Carcinoma, Non Hodgkin Lymphoma, Endometrial Cancer
11/21
12/24
NCT02637531: A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Checkmark From MARIO-1 trial in combination with IPI-549 for solid tumors
Nov 2020 - Nov 2020: From MARIO-1 trial in combination with IPI-549 for solid tumors
Checkmark From P1/1b trial in combination with IPI-549 for advanced solid tumors
Nov 2020 - Nov 2020: From P1/1b trial in combination with IPI-549 for advanced solid tumors
Checkmark Clinical & translational data from expansion cohorts of MARIO‑1 phase 1b study in combination with Opdivo
More
Active, not recruiting
1
219
US
IPI-549 (eganelisib), Nivolumab, OPDIVO
Infinity Pharmaceuticals, Inc.
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
01/22
12/22
MESOVAX, NCT03546426: Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Recruiting
1
18
Europe
Pembrolizumab, Autologous dendritic cells, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
01/22
01/24
NCT04345705: Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Not yet recruiting
1
18
US
Poly ICLC, Hiltonol®
Raja M Flores, Oncovir, Inc.
Mesothelioma
05/22
05/22
NCT04489862: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Recruiting
1
10
RoW
αPD1-MSLN-CAR T cells
Wuhan Union Hospital, China, Shanghai Cell Therapy Group Co.,Ltd
Non-small-cell Lung Cancer, Mesothelioma
06/22
12/22
LuPARP, NCT04375267: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Active, not recruiting
1
18
Europe
177Lu-DOTA-TATE + olaparib
Vastra Gotaland Region, Advanced Accelerator Applications
Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
06/24
06/24
8479217, NCT06469138: A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects

Completed
1
6
Europe
Bemcentinib, BGB324
BerGenBio ASA
Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Metastatic Pancreatic Cancer, Glioblastoma, Malignant Mesothelioma, COVID-19
09/22
09/22
NCT03852823: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Recruiting
1
192
RoW
SG001, Recombinant Human Anti-PD-1 Monoclonal Antibody
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma, Non-Small-Cell Lung Cancer
09/22
03/23
NCT03228537: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Active, not recruiting
1
28
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Pleurectomy, Excision of Pleura, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7, Stage IA Pleural Malignant Mesothelioma AJCC v7, Stage IB Pleural Malignant Mesothelioma AJCC v7, Stage II Pleural Malignant Mesothelioma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7
10/22
09/24
NCT04042480: A Study of SGN-CD228A in Advanced Solid Tumors

Terminated
1
88
Europe, US
SGN-CD228A
Seagen Inc.
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
03/23
03/23
NCT04537715: Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Completed
1
42
Europe, US
Tazemetostat, EPZ-6438, Tazverik, Itraconazole, Sporanox, Rifampin, RIF, Rifampicin, Rifadin, Rimactane
Epizyme, Inc.
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
04/23
04/23
MESO-PRIME, NCT04166734: Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

Terminated
1
3
Europe
Pembrolizumab, Keytruda, Stereotactic Body Radiotherapy (SBRT), SBRT
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Advanced Malignant Pleural Mesothelioma
07/23
07/23
NCT04525859: Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Recruiting
1
19
US
Safety, Expansion Cohort
Oncovir, Inc., Icahn School of Medicine at Mount Sinai
Malignant Pleural Mesothelioma
08/23
08/24
DIONE-01, NCT04328844: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, not recruiting
1
210
Europe
IOA-244, Avelumab Injection, Pemetrexed, Cisplatin, Ruxolitinib
iOnctura
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
09/23
04/24
PITHAC, NCT06281860: Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

Recruiting
1
39
Europe
Cisplatine Teva®, Procedure/Surgery
Dr Jean Yannis PERENTES
Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast Stage IV, Ovarian Cancer, Esophageal Cancer, Gastric Cancer
12/25
02/26
NCT03590054: Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Checkmark Interim data in combination with abexinostat for multiple solid tumors
Aug 2019 - Aug 2019: Interim data in combination with abexinostat for multiple solid tumors
Completed
1
35
US
Abexinostat, PCI-24781, Pembrolizumab, Keytruda
Rahul Aggarwal, Xynomic Pharmaceuticals, Inc.
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
11/23
11/23
NCT03420963: Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Recruiting
1
38
US
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Allogeneic CB-derived Ex vivo-expanded NK Cells, CB-derived Expanded Allogeneic NK Cells, UCB-derived Expanded Allogeneic NK Cells, Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
12/27
12/27
AURELIO-03, NCT04234113: Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Active, not recruiting
1
200
Europe, US, RoW
SO-C101, SOT101, pembrolizumab
SOTIO Biotech AG, SOTIO Biotech a.s.
Thyroid, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
08/24
11/24
NCT02748798: Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

Recruiting
1
160
Canada
HP 3He, Hyperpolarized helium 3, HP 129Xe, Hyperpolarized xenon 129, PFP, Perfluoropropane, SF6, Sulfur hexafluoride, 129Xe Small and Large Human Lung Coil, 3He Human Lung Coil, PFP and SF6 Human Lung Coil
Thunder Bay Regional Health Research Institute, Thunder Bay Regional Health Sciences Centre, St. Joseph's Care Group, Lakehead University
Lung Transplant, Lung Resection, Lung Cancer, Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Emphysema, Mesothelioma, Asbestosis, Pulmonary Embolism, Interstitial Lung Disease, Pulmonary Fibrosis, Bronchiectasis, Seasonal Allergies, Cold Virus, Lung Infection, Pulmonary Hypertension, Pulmonary Dysplasia, Obstructive Sleep Apnea
12/23
12/23
NCT04491942: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Active, not recruiting
1
74
Canada, US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011
National Cancer Institute (NCI)
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
06/25
06/25
NCT01766739: Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Active, not recruiting
1
18
US
GL-ONC1
Memorial Sloan Kettering Cancer Center, Genelux Corporation
Lung Cancer
01/25
01/25
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours

Recruiting
1
30
RoW
AMT-151
Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd
Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma
01/24
10/24
NCT04840615: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Terminated
1
2
US
LMB-100, ipilimumab, Yervoy, Diphenhydramine, Benadryl, Famotidine, Pepcid, Acetaminophen, Tylenol, Dexamethasone, Ozurdex, Biopsy, FDG-PET, Fluorodeoxyglucose-positron emission tomography, CT CAP, Computed tomography of the chest, abdomen and pelvis, MRI, Magnetic resonance imaging, ECG, Electrocardiogram, Echocardiogram, Echo
National Cancer Institute (NCI)
Mesothelioma
12/21
01/22
KEYNOTE-E13, NCT05215574: Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Recruiting
1
130
US
NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
NGM Biopharmaceuticals, Inc, Merck Sharp & Dohme LLC
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
07/25
03/26
KEYNOTE-E20, NCT05311618: Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Active, not recruiting
1
71
US
NGM438, Pembrolizumab (KEYTRUDA ®)
NGM Biopharmaceuticals, Inc, Merck Sharp & Dohme LLC
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
04/25
06/25
UCMYM802-Ⅰ, NCT06256055: Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Recruiting
1
24
RoW
UCMYM802 Injection
UTC Therapeutics Inc., Peking University Cancer Hospital & Institute
Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer Female
03/25
04/25
NCT02959463: Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Active, not recruiting
1
24
US
Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Pleural Malignant Mesothelioma
04/24
04/24
NCT06299163: NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Recruiting
1
180
US
NM32-2668
Numab Therapeutics AG
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
12/27
12/27
NCT06196294: GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Recruiting
1
30
RoW
Cell therapy for solid tumors
Second Affiliated Hospital of Guangzhou Medical University
Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma, CAR-T Cell Therapy, Solid Tumor, Adult
11/30
12/36
BGC515-101, NCT06452160: A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Recruiting
1
103
US
BGC515
BridGene Biosciences Inc.
Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
06/27
12/27
NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Active, not recruiting
1
10
US
Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF
Memorial Sloan Kettering Cancer Center
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
07/24
07/24
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors

Recruiting
1
186
US
SW-682, Combination Therapy
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
01/30
06/30
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
240
US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx, Inc.
Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors
12/25
07/26
STEALTH-001, NCT06444815: A Study of VET3-TGI in Patients With Solid Tumors

Not yet recruiting
1
60
NA
VET3-TGI, Pembrolizumab
KaliVir Immunotherapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
09/27
12/27
NCT06466187: A Study of SGN-MesoC2 in Advanced Solid Tumors

Not yet recruiting
1
365
NA
SGN-MesoC2, HBM9033
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors
11/28
11/28
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/24
02/26
NCT04577326: Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Recruiting
1
30
US
cyclophosphamide, CAR T cells
Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics
Malignant Pleural Mesothelioma (MPM)
09/25
09/25
NCT05071014: A Study of Pembrolizumab and Cryoablation in People With Mesothelioma

Completed
1
2
US
Pembrolizumab, Image-guided cryoablation
Memorial Sloan Kettering Cancer Center
Lung Cancer, Unresectable Mesothelioma
12/23
12/23
NCT05415098: Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Recruiting
1
90
US
APG-5918
Ascentage Pharma Group Inc.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
09/24
09/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Active, not recruiting
1
198
Europe, US
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
06/25
06/25
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
74
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy
12/25
06/26
HFB-200301-01, NCT05238883: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Recruiting
1
170
Europe, US
HFB200301, Tislelizumab, BGB-A317
HiFiBiO Therapeutics
Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
12/26
12/26
NCT05538572: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1
22
US, RoW
PRT3645
Prelude Therapeutics
Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer
06/24
06/24
ENSURE, NCT05304208: dENdritic Cell Therapy Combined With SURgEry in Mesothelioma

Recruiting
1
16
Europe
Mesopher
Erasmus Medical Center
Mesotheliomas Pleural
12/24
12/25
NCT03760575: Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Recruiting
1
20
US
Pembrolizumab, MK-3475, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin, Pemetrexed
Abramson Cancer Center at Penn Medicine
Mesotheliomas Pleural
12/24
12/24
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting
1
150
RoW
APG-2449, APG-2449 Capsule
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma
01/25
02/25
TOAST IT, NCT04213794: Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Recruiting
1
43
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cytoreductive Surgery, Cytoreduction, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Hyperthermic Intraperitoneal Chemotherapy, HIPEC, Sodium Thiosulfate, Cyanide Antidote Package, Disodium Thiosulfate, S-Hydril, Sodium Hyposulfate, Sodium Thiosulfate Pentahydrate, Sodium Thiosulphate, Sodothiol, Thiosulfate, Sodium, Pentahydrate, Thiosulfuric Acid Disodium Salt, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computed Tomography (CT), CT Scan, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MRI, MRI Scan, Nuclear Magnetic Resonance Imaging, NMRI, Structural MRI, sMRI, Positron Emission Tomography, Medical Imaging, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
Mayo Clinic, National Cancer Institute (NCI)
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
01/25
01/25
KEYNOTE-E65, NCT03881488: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Recruiting
1
157
US
CTX-471, Pembrolizumab (KEYTRUDA®), KEYTRUDA®
Compass Therapeutics, Iqvia Pty Ltd, Merck, Sharp & Dohme, LLC, Rahway, NJ USA
Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
02/25
04/25
 

Download Options